For informational purposes only — not investment advice

← Back to signals

AVTX

Avalo Therapeutics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
2.1d↓-21.9%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Negative

Avalo reported Q3 2026 narrowed losses and maintains $462.8M cash runway into 2029, but the company faces significant clinical and strategic headwinds: a wave of analyst downgrades in late October citing IL-1 program concerns triggered a 44% stock plunge, and management is actively exploring strategic alternatives and pipeline pruning to streamline operations. The Phase 3 program initiation now hinges on FDA feedback expected by year-end 2026, creating near-term binary risk.

Red flags

  • •Wave of analyst downgrades (H.C. Wainwright downgrade to Neutral, Wedbush price target cut from $34 to $22) in October 2026 citing IL-1 program clinical concerns
  • •Stock plunged ~44% over five sessions following downgrades, indicating loss of investor confidence
  • •Company exploring 'strategic alternatives' for lead asset AVTX-010 and pipeline pruning, signaling potential pivot or asset sales under pressure
  • •Phase 3 program initiation delayed to H1 2027 pending FDA feedback expected by year-end 2026 (binary event risk)
  • •Implicit clinical trial setback or development plan concerns driving analyst downgrades, though specific trial data not disclosed

Fund 13D/13G Filings (3)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Point72SC 13G/A−1.1M3.0%
-5.2% vs SPY
-8.4% abs
2026-11-16↗
Point72SC 13GNEW5.2%
+18.3% vs SPY
+20.3% abs
2026-05-26↗
Point72SC 13G/A—3.5%—2026-02-17↗

Tracked Funds Holding (1)

FundManagerShares HeldPosition Value
Point72Steve Cohen1.6M$25M

Quarter-end 13F positions for the tracked funds holding this stock.